Phase I trial of the ATR inhibitor BAY 1895344 combined with stereotactic body radiation therapy and pembrolizumab for recurrent head and neck squamous cell carcinoma.
Year: 2022
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: Duke Medical Center, Duke University
Language: English
Topic: Head and Neck Cancer Studies
Subfield: Otorhinolaryngology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: National Institutes of Health
OpenAlex ID: W4286297616